SeMaglutide and Albuminuria Reduction Trial in obese individuals without diabetes
- Conditions
- Obesity and chronic kidney disease1000054610029149
- Registration Number
- NL-OMON50899
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 40
• Age >= 18 years
• Body Mass index >= 27 kg/m2
• Albuminuria >= 30 mg/g and <= 3500 mg/g
• eGFR >= 25 ml/min/1.73m2
• Stable renal function prior to entry into the study defined as no more than
30% eGFR change in
3 months prior to enrolment
• Signed Informed Consent
• Diagnosis with type 1 or type 2 Diabetes
• Hba1c >= 6.5% at screening
• Cardiovascular disease event in 3 months prior to enrollment
• Treatment with GLP-1 RA < 4 weeks prior to screening
• Uncontrolled thyroid disease TSH>6.0 mIU/L or <0.4 mIU/L at screening
• Acute pancreatitis < 180 days prior to screening
• History or presence of chronic pancreatitis
• Females of child-bearing potential who are pregnant, breast-feeding or have
intention of
becoming pregnant or are not using adequate contraceptive measures
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.